特立妥单抗用于重度经治的复发/难治性多发性骨髓瘤伴肾功能损害患者
该研究评估了标准治疗特立妥单抗在伴肾功能损害(肌酐清除率<40 mL/min)的复发/难治性多发性骨髓瘤患者中的疗效与安全性。384例患者中81例(21%)伴肾功能损害,其中45例(18%)为严重肾功能损害、18例(5%)接受透析。肾功能损害患者与无肾功能损害患者的总体缓解率(52% vs 56%;P = .61)和生存结局(中位无进展生存期4.6 vs 6.5个月;P = .62)相当,细胞因子释放综合征和免疫效应细胞相关神经毒性综合征的发生率与严重程度相似。
要点
- 伴肾功能损害患者与无肾功能损害患者的总体缓解率分别为52%与56%(P = .61),无显著差异。
- 中位无进展生存期在伴与不伴肾功能损害患者中分别为4.6个月与6.5个月(P = .62)。
- 伴肾功能损害患者基线及第30天≥3级贫血和≥3级血小板减少发生率更高。
核心结论
- 研究结果提示,特立妥单抗用于伴肾功能损害(包括接受透析)的复发/难治性多发性骨髓瘤患者是可行的,其安全性和疗效特征与无肾功能损害患者相似。
研究设计与样本
- 研究纳入384例接受标准治疗特立妥单抗的复发/难治性多发性骨髓瘤患者,其中81例(21%)伴肾功能损害,45例(18%)为严重肾功能损害,18例(5%)接受透析;肾功能损害定义为肌酐清除率<40 mL/min,严重肾功能损害定义为肌酐清除率<30 mL/min或依赖透析。
主要发现
- 伴肾功能损害患者较无肾功能损害患者年龄更大(中位年龄71 vs 67岁;P = .002),既往治疗线数中位数更多(7 vs 6;P = .04)。
- 细胞因子释放综合征发生率在伴与不伴肾功能损害患者中分别为51%与59%(≥3级:1.2% vs 1%),免疫效应细胞相关神经毒性综合征发生率分别为16%与13%(≥3级:2.5% vs 2.6%)。
- 伴肾功能损害患者基线及特立妥单抗治疗后第30天的≥3级贫血和≥3级血小板减少发生率更高。
- 在非疾病进展背景下,大多数伴肾功能损害患者开始特立妥单抗治疗后肾功能未恶化。
- 中位随访9.9个月时,伴与不伴肾功能损害患者的总体缓解率分别为52%与56%(P = .61),中位无进展生存期分别为4.6个月与6.5个月(P = .62),总生存期或非复发死亡率未见差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Outcomes of bispecific antibodies in patients with renal impairment (RI) are not well characterized, given the exclusion of these patients from clinical trials. Herein, we evaluated patients with relapsed/refractory multiple myeloma and RI treated with standard-of-care teclistamab. RI was defined as creatinine clearance (CrCl) <40 mL/min. CrCl <30 mL/min or dialysis dependence was defined as severe RI. Of the 384 included patients, 81 (21%) had RI, including 45 (18%) with severe RI, and 18 (5%) on dialysis. Patients with RI were more likely to be older (median age, 71 vs 67 years; P = .002) and have a higher median number of previous lines of therapy (7 vs 6; P = .04). Rates and severity of cytokine release syndrome (51% vs 59%; grade ≥3: 1.2% vs 1%) and immune effector cell-associated neurotoxicity syndrome (16% vs 13%; grade ≥3: 2.5% vs 2.6%) were similar in patients with and without RI, respectively. Patients with RI had higher baseline and day 30 post-teclistamab grade ≥3 anemia and grade ≥3 thrombocytopenia. Renal function did not worsen after teclistamab initiation in most patients with RI outside of the context of disease progression. Overall response rate (52% vs 56%; P = .61) and survival outcomes (median progression-free survival, 4.6 vs 6.5 months; P = .62) were comparable in patients with and without RI, respectively, after a median follow-up of 9.9 months. No differences in overall survival or non-relapse mortality were noted. Our findings suggest that treatment with teclistamab is feasible in patients with RI, including those on dialysis, with a similar safety and efficacy profile to patients without RI.
引用
- Dima D, Afrough A, Goel U, et al. Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment. Blood Adv. 2025. PMID: 40198766. doi:10.1182/bloodadvances.2025016059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。